Form D · Pharmaceuticals
IGENICA BIOTHERAPEUTICS, INC
Burlingame, CA · CIK 0001453044
Offering snapshot reported Oct 14, 2015 · SEC filing
- Reported sold
- $2.25M Offering amount: $5M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 29, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2015 | Initial | $2,250,001 | No comparison | 10 | SEC filing |
| Jun 9, 2015 | Initial | $1,233,334 | No comparison | 8 | SEC filing |
| Jan 26, 2015 | Initial | $5,051,844 | No comparison | 10 | SEC filing |
| Feb 7, 2014 | Initial | $7,033,558 | No comparison | 7 | SEC filing |
| Dec 4, 2012 | Amendment | $20,295,000 | $10,250,000vs Jun 22, 2012 | 8 | SEC filing |
| Oct 11, 2012 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 22, 2012 | Initial | $10,045,000 | No comparison | 7 | SEC filing |
| May 2, 2012 | Initial | $0 | No comparison | 1 | SEC filing |
| Sep 28, 2011 | Amendment | $16,083,332 | $8,041,666vs May 4, 2010 | 6 | SEC filing |
| Sep 9, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| May 4, 2010 | Initial | $8,041,666 | No comparison | 6 | SEC filing |
| Jul 17, 2009 | Initial | $0 | No comparison | 1 | SEC filing |
| Dec 23, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-249373
Source: Form D, filed Oct 14, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luis Bayol | Executive |
| John Celebi | Executive |
| Guoqing Chen | Executive |
| John Diekman | Director |
| Gwen Fyfe | Director |
| David Goeddel | Director |
| Mark Goldsmith | Director |
| Carl Gordon | Director |
| Mary Haak Frendscho | Director, Executive |
| Mike Rothe | Director, Executive |
| Robert Schreiber | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
863 A Mitten Rd. Suite 100 B
Burlingame, CA, 94040
Burlingame, CA, 94040